Sygnature Discovery, a drug discovery contract research organization (CRO), announced Susanne Back as its new Head of In Vivo Pharmacology. The company has recently launched a strategic rebrand reflecting its two-plus decades of growth, investment, and targeted acquisitions. Makeup of Sygnature In Vivo Team Back will oversee approximately 30 scientists, working with both clients and multidisciplinary project teams to deliver robust in-vivo strategies. Her responsibilities include...